Breast cancer returns in one in five cases
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.More than one in five breast cancer patients sees the disease return, a new study has found.
Macmillan Cancer Support concluded that 22.6 per cent of patients will suffer a recurrence. The charity examined the cases of just under 1,000 patients treated from January 1999 onwards.
Half of the patients who developed recurrent disease did not get any new tumours for more than three years, according to the researchers from St James's Institute of Oncology in Leeds.
The co-author of the study, Dr Adam Glaser, said the results were "invaluable". He explained: "The aim of this study is to begin to understand more about how long people may survive without recurrence, how long they may survive if cancer does return, the cost of each stage of cancer treatment, and how we can best plan services for cancer patients."
Jane Maher, chief medical officer at Macmillan Cancer Support, added: "Not only do these women have to deal with the shock of their breast cancer returning, but far too many are given very little practical or emotional support."
The full findings will be presented at the National Cancer Intelligence Network conference in Birmingham later this week.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments